文献速递眼整形与眼眶神经眼科

0.1%盐酸羟甲唑啉滴眼液与获得性上睑下垂视野的关联:两项随机临床试验的汇总分析

Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical Trials.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该汇总分析纳入两项随机双盲安慰剂对照3期试验,共304例9岁及以上获得性上睑下垂伴上方视野缺损患者,随机2:1接受0.1%羟甲唑啉或溶媒滴眼,每日一次,共42天。结果显示0.1%羟甲唑啉在第1天和第14天显著改善Leicester周边视野测试点数及边缘反射距离1,且耐受性良好。

要点

  • 0.1%羟甲唑啉在第1天和第14天显著增加Leicester周边视野测试点数,优于溶媒。
  • 0.1%羟甲唑啉在第1天和第14天显著增加边缘反射距离1,优于溶媒。
  • 治疗中出现的不良事件发生率在羟甲唑啉组为31.0%,溶媒组为35.6%,多数为轻度。

核心结论

  • 0.1%羟甲唑啉滴眼液在3期试验中第1天和第14天滴眼后与阳性结果相关且耐受性良好,显示其治疗获得性上睑下垂的潜在前景,但需进一步研究以阐明这些发现超过6周的临床相关性。

研究设计与样本

  • 两项随机、双盲、安慰剂对照、多中心3期临床试验的汇总分析,纳入9岁及以上获得性上睑下垂伴上方视野缺损的参与者,随机2:1接受0.1%羟甲唑啉或溶媒,每眼一滴、每日一次,共42天。
  • 两项研究分别在美国16个和27个中心进行,患者入组时间为2015年5月至2019年4月。
  • 共纳入304例参与者,平均(标准差)年龄63.8(13.8)岁,女性222例(73%)。
  • 0.1%羟甲唑啉组97.5%(198/203)和溶媒组97.0%(98/101)的参与者完成了研究。

主要发现

  • 治疗中出现的不良事件发生率在0.1%羟甲唑啉组为31.0%(63/203),溶媒组为35.6%(36/101);羟甲唑啉组发生不良事件的参与者中81%(51/63)最大强度为轻度,62%(39/63)无怀疑与治疗相关的不良事件。

关键数值与推荐

  • 主要疗效终点为第1天(滴眼后6小时)和第14天(滴眼后2小时)Leicester周边视野测试点数较基线的变化。
  • 次要终点为相同时间点边缘反射距离1较基线的变化。

临床怎么用

  • 0.1%羟甲唑啉滴眼液每日一次可能改善获得性上睑下垂患者的上方视野和睑裂高度,且耐受性良好。
  • 需进一步研究以阐明超过6周的临床相关性。

局限性

  • 研究仅评估至第14天,结论中提及需进一步研究以阐明超过6周的临床相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment of acquired blepharoptosis (ptosis) is currently limited to surgical intervention. OBJECTIVE: To examine the efficacy and safety of oxymetazoline hydrochloride, 0.1%, ophthalmic solution (oxymetazoline, 0.1%) in participants with acquired ptosis. DESIGN, SETTING, AND PARTICIPANTS: This pooled analysis of 2 randomized, double-masked, placebo-controlled, multicenter phase 3 clinical trials included participants 9 years and older with acquired ptosis and superior visual field deficit. The 2 studies were conducted across 16 and 27 sites in the United States. Patients were enrolled from May 2015 to April 2019. Analyses for the individual trials were initiated after database lock and completed on September 6, 2017, and May 16, 2019. Pooled analysis was completed on August 25, 2019. INTERVENTIONS: Participants (randomized 2:1) received oxymetazoline, 0.1%, or vehicle, self-administered as a single drop per eye, once daily, for 42 days. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was change from baseline in the number of points seen on the Leicester Peripheral Field Test, a test to detect superior visual field deficits due to ptosis, on days 1 (6 hours after instillation) and 14 (2 hours after instillation). The secondary end point, change from baseline in marginal reflex distance 1, was assessed at the same time points. RESULTS: In total, 304 participants were enrolled (mean [SD] age, 63.8 [13.8] years; 222 women [73%]). Overall, 97.5% (198 of 203) of participants receiving oxymetazoline, 0.1%, and 97.0% (98 of 101) of participants receiving vehicle completed the studies. Oxymetazoline, 0.1%, was associated with a significant increase in the mean (SD) number of points seen on the Leicester Peripheral Field Test vs vehicle (day 1: 5.9 [6.4] vs 1.8 [4.1]; mean difference, 4.07 [95% CI, 2.74-5.39]; P < .001; day 14: 7.1 [5.9] vs 2.4 [5.5]; mean difference, 4.74 [95% CI, 3.43-6.04]; P < .001). Oxymetazoline, 0.1%, also was associated with a significant increase in marginal reflex distance 1 from baseline (mean [SD]: day 1: 0.96 [0.89] mm vs 0.50 [0.81] mm; mean difference, 0.47 mm [95% CI, 0.27-0.67]; P < .001; day 14: 1.16 [0.87] mm vs 0.50 [0.80] mm; mean difference, 0.67 mm [95% CI, 0.46-0.88]; P < .001). Treatment-emergent adverse events (TEAEs) occurred in 31.0% (63 of 203) of participants receiving oxymetazoline, 0.1%, and 35.6% (36 of 101) of participants receiving vehicle. Among participants receiving oxymetazoline, 0.1%, with a TEAE, 81% (51 of 63) had a maximum TEAE intensity of mild, and 62% (39 of 63) had no TEAE suspected of being treatment related. CONCLUSIONS AND RELEVANCE: Oxymetazoline, 0.1%, was associated with positive outcomes and was well tolerated in phase 3 trials after instillation at days 1 and 14, demonstrating its potential promise for the treatment of acquired ptosis, although further study is needed to elucidate the clinical relevance of these findings beyond 6 weeks.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Slonim CB, Foster S, Jaros M, et al. Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical Trials. JAMA Ophthalmol. 2020. PMID: 33001144. doi:10.1001/jamaophthalmol.2020.3812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。